Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌ESCC
A cancer that usually starts in cells on the surface of the middle and lower parts of the oesophagus.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 192
- cities
- 67
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 69% of the world's English-language research papers on oesophageal squamous cell carcinoma, 2021–2025 (56% in 2016–2020), and 55% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
192 hospitals in 67 cities
Order: papers led on oesophageal squamous cell carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 3 papers or 1 trial on oesophageal squamous cell carcinoma, or was a site in 3 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens oesophageal squamous cell carcinoma in that city. 57 more cities are in the menu below.
- 184 papers led
- 137 papers led
- 123 papers led
- 82 papers led
- 79 papers led
- 71 papers led
- 66 papers led
- 65 papers led
- 56 papers led
- 50 papers led
- 50 papers led
- 49 papers led
- 47 papers led
- 41 papers led
- 40 papers led
- 36 papers led
- 32 papers led
- 32 papers led
- 31 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers led
- 27 papers ledNo open trial led
- 26 papers ledNo open trial led
- 25 papers led
- 23 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers led
- 22 papers ledNo open trial led
- 22 papers led
- 22 papers ledNo open trial led
- 20 papers led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 18 papers led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers led
- 15 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers led
- 10 papers led
- 10 papers led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 55
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 203 papers led6 hospitals
- 200 papers led5 hospitals
- 179 papers led6 hospitals
- 134 papers led6 hospitals
- 109 papers led6 hospitals
- 108 papers led6 hospitals
- 105 papers led6 hospitals
- 104 papers led6 hospitals
- 90 papers led5 hospitals
- 82 papers led6 hospitals
- 72 papers led2 hospitals
- 66 papers led1 hospital
- 56 papers led4 hospitals
- 55 papers led2 hospitals
- 50 papers led1 hospital
- 49 papers led5 hospitals
- 41 papers led6 hospitals
- 37 papers led3 hospitals
- 37 papers led2 hospitals
- 32 papers led6 hospitals
- 30 papers led6 hospitals
- 29 papers led6 hospitals
- 28 papers led5 hospitals
- 27 papers led1 hospital
- 26 papers led5 hospitals
- 26 papers led3 hospitals
- 25 papers led6 hospitals
- 22 papers led3 hospitals
- 22 papers led1 hospital
- 20 papers led5 hospitals
- 20 papers led3 hospitals
- 20 papers led6 hospitals
- 19 papers led4 hospitals
- 19 papers led1 hospital
- 19 papers led6 hospitals
- 17 papers led4 hospitals
- 16 papers led3 hospitals
- 15 papers led2 hospitals
- 14 papers led3 hospitals
- 12 papers led2 hospitals
- 12 papers led1 hospital
- 11 papers led3 hospitals
- 11 papers led4 hospitals
- 11 papers led3 hospitals
- 9 papers led2 hospitals
- 9 papers led2 hospitals
- 8 papers led3 hospitals
- 7 papers led2 hospitals
- 6 papers led3 hospitals
- 6 papers led1 hospital
- 5 papers led1 hospital
- 5 papers led2 hospitals
- 4 papers led2 hospitals
- 4 papers led1 hospital
- 3 papers led2 hospitals
open trials on oesophageal squamous cell carcinoma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 168 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingNeoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07244978
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07246330
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07385001
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingBecotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07403136
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07405151
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou
- RecruitingTime-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07452601
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingEfficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07457528
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07463573
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCamrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07505186
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingIntensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07519486
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Registry
- NCT07554456
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingInduction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07559045
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Zunyi Medical UniversityZunyi
- RecruitingAdebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07595770
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07627347
Age 18 years to 70 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingSurgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07629817
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingPD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07697859
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07700667
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingComparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07733830
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou
- RecruitingA Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07751341
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou
- RecruitingInterferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07787273
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingSacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07811752
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingRadiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07858630
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07863141
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingBecotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07892833
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu
- RecruitingA Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06356688
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT06753747
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06769113
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06780111
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06843889
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06869213
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingNeoadjuvant QL1706 Therapy for ESCC
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06908382
Age 18 years to 75 years (registered criteria)
Led by Shandong Provincial HospitalJinan
- RecruitingHypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06912074
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingCCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06964568
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingChemoradiation Plus Iparomlimab Consolidation in Older With ESCC
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07038629
Age 70 years to 90 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingQL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07049185
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingPatient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07054086
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingOncolytic Virus in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07061704
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSurufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07086469
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDeep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07088354
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07090499
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingdCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07162506
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingConsolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07177794
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingIvonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07188103
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingPerioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07263919
Lead sponsor is not a listed hospital; 1 listed hospital as study siteXi'an
- RecruitingClinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07266480
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingThe Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07290010
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07317609
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingIntestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07339488
Age 18 years to 75 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- RecruitingExploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07435454
Age 70 years to Not stated (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- RecruitingKC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07481058
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingShort-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07530094
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingExploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07622797
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Henan University of Science and TechnologyLuoyang
- RecruitingAdebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07796113
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- RecruitingA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
- Phase
- Phase 3
- Started
- 2024-02
- Registry
- NCT06194734
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAdjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06272214
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingPembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06304350
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCombination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06339619
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06342167
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan
- RecruitingPPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06354140
Age 18 years to 75 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingNeoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06385730
Age 76 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingShort-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06408584
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingSintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06413342
Age 70 years to 85 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingInduction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06421376
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang
- RecruitingNeoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06430658
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingLow-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06446726
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingInduction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06452602
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06463834
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingAK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06489197
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06509568
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingAdebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06510660
Age 18 years to 70 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingIndividualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06561178
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2024-02
- Registry
- NCT06563869
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingAdbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06576973
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingLymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06596954
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBiomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06601309
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingNeoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06602843
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingBenmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06637163
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin
- RecruitingFruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06646588
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingAdebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06663059
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingNeoantigen Vaccines in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06675201
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingTDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06676449
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06684600
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingTrilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06698692
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06709417
Age 20 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingOptimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06907602
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06988956
Age 75 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingNeoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT07016724
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingAdebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT07430579
Age 18 years to 80 years (registered criteria)
Led by Second Hospital of Shandong University; 1 listed hospital as study siteJinan
- RecruitingNeoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT07437898
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Putian UniversityPutian
- RecruitingNeoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT07699185
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPostoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
- Phase
- N/A
- Started
- 2023-05
- Registry
- NCT03734952
Age 18 years to 65 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Phase
- Phase 1/Phase 2
- Started
- 2023-05
- Registry
- NCT05319730
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou
- RecruitingCamrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05738434
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingWhole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT05833594
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingInfluence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT05894369
Age 18 years to 80 years (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingA Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2023-07
- Registry
- NCT05919030
Age 18 years to Not stated (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingPostoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Registry
- NCT05937438
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingMinimally Residual of Esophageal Cancer 001
- Phase
- Not given
- Started
- 2023-02
- Registry
- NCT05952661
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingRadiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT05978193
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 1 listed hospital as study siteShanghai
- RecruitingAdjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT05984342
Age 18 years to 70 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- RecruitingPerioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06056336
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingImmunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-01
- Registry
- NCT06173986
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06190639
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingSerplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06354218
Age 75 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingNimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT06410651
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingNimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT06429839
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingNimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT06718205
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingEfficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT07266493
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingEfficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT07549100
Age 18 years to 75 years (registered criteria)
Led by Shandong Provincial HospitalJinan
- RecruitingNeoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
- Phase
- Phase 2/Phase 3
- Started
- 2022-03
- Registry
- NCT04973306
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05182944
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingPenpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05214222
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT05252078
Age 18 years to Not stated (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingSurgery or Chemoradiotherapy for Cervical Esophageal Cancer
- Phase
- N/A
- Started
- 2022-04
- Registry
- NCT05327517
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingPD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05357846
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingImmune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
- Phase
- Not given
- Started
- 2022-08
- Registry
- NCT05392413
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingValue of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05443841
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou
- RecruitingAdjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2022-08
- Registry
- NCT05495152
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingWatch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT05507411
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingInduction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-05
- Registry
- NCT05515315
Age 18 years to 70 years (registered criteria)
Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou
- RecruitingNeoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT06006650
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingLocal Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT06190782
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
- Phase
- Phase 3
- Started
- 2021-01
- Registry
- NCT04415853
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
- Phase
- Phase 3
- Started
- 2021-12
- Registry
- NCT04807673
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingComparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
- Phase
- N/A
- Started
- 2021-06
- Registry
- NCT05775419
Age 18 years to 70 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingAn Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2021-03
- Registry
- NCT07080437
Age 70 years to Not stated (registered criteria)
Led by Chongqing University Three Gorges HospitalChongqing
- RecruitingNeo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
- Phase
- Phase 3
- Started
- 2020-04
- Registry
- NCT04280822
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingPhase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
- Phase
- N/A
- Started
- 2020-01
- Registry
- NCT04519905
Age 76 years to Not stated (registered criteria)
Led by Huadong Hospital, Fudan University; 1 listed hospital as study siteNanjing, Shanghai
- RecruitingNeoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT05740995
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingNeoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2019-04
- Registry
- NCT03964753
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingComparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2019-09
- Registry
- NCT04135664
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin
- RecruitingNeoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
- Phase
- Phase 3
- Started
- 2019-10
- Registry
- NCT04138212
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingStudy on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2019-12
- Registry
- NCT04174079
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingChemoradiotherapy in Unresectable Esophageal Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-10
- Registry
- NCT04278287
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing
- RecruitingChemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
- Phase
- N/A
- Started
- 2016-11
- Registry
- NCT02972372
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Henan University of Science and Technology; 1 listed hospital as study siteAnyang, Luoyang
- RecruitingInfluence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT04522687
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingNeoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT06952621
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingIndocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07376876
Age 18 years to 80 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingShort-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07403435
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07446335
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingClinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07493993
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingSHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07524374
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingProspective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07531979
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingRetlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07618910
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingNeoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07678580
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingA Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07688291
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- Not yet recruitingBecotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07697040
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingSacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07701681
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingEarly Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07721103
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingStandardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07769658
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou
- Not yet recruitingRetlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
- Phase
- N/A
- Started
- 2026-09
- Registry
- NCT07769866
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingAn Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07770672
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingStudy of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07780721
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Putian UniversityPutian
- Not yet recruitingA Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Registry
- NCT07788001
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingPaclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07799077
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingRisk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07822906
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingNeoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07823270
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingNeoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06814158
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingTotal Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06861777
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingActive Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT06861894
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingPrognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06889402
Age 18 years to 85 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingToripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06903871
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingDefinitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07034118
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- Not yet recruitingA Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07112833
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingEndostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07154108
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingRAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06012214
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingA Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06487702
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingCadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06681285
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingSafety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06756841
Age 20 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Registry
- NCT06136988
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06152978
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingNeoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06178211
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingSintilimab Plus NCT or NCRT Versus NCRT for ESCC
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05244798
Age 18 years to 75 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingPembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-12
- Registry
- NCT05386056
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingTwo-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05420480
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Enrolling by invitationDiagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06984055
Age 18 years to 85 years (registered criteria)
Led by Changhai HospitalShanghai
- Enrolling by invitationNimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07312578
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Enrolling by invitationBased on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07371247
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationInfiltration Pattern of Locally Advanced ESCC
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07567716
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Enrolling by invitationEvaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Registry
- NCT06690216
Age 18 years to Not stated (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Enrolling by invitationEfficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06715501
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Ningbo UniversityNingbo
- Enrolling by invitationA Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06863831
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationImmunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT07016737
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- Enrolling by invitationA Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-11
- Registry
- NCT06160557
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial HospitalFuzhou
- Enrolling by invitationCarrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT06048926
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationNeoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2022-06
- Registry
- NCT06303583
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Guidelines for cancers and blood diseases (2022 edition)National Health Commission 国卫办医函〔2022〕104号, 2022-04-11
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.